Valproate is currently one of the most frequently prescribed drugs in schizophrenia spectrum disorders. However, surprisingly little is known from controlled studies. Also, no review articles are available. Here, we summarize basic and clinical research on valproate and its application for treatment in schizophrenia spectrum disorders. The molecular and physiological effects of valproate are outlined. It is discussed how the effects of valproate on the cellular level involving serotonin, GABA, glutamate, sodium-channels, membrane fluidity and RNA-expression may account for its clinical effect in schizophrenia spectrum patients. The target symptoms are a reduction of psychomotor agitation and aggression, possibly reflecting a drug effect on temporal lobe pathology, which is considered to be involved in the etiology of schizophrenic illness.
References
-
1
Adler L E, Olincy A, Waldo M, Harris J G, Griffith J, Stevens K, Flach K, Nagamoto K, Blickford P, Leonard S, Freedman R.
Schizophrenia, sensory gating, and nicotinic receptors.
Schiz Bull.
1998;
24
189-202
-
2
Albus H, Williamson R.
Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice.
Epilepsia.
1998;
39
124-139
-
3 Angst J, Stassen H H, Gross G, Huber G, Stone M H. Suicide in affective and shcizoaffective disorders. In: Maneros A, Tsuang MT (eds) Affective and schizoaffective disorders. Berlin; Springer 1990: 168-186
-
4
Altamura A C, Basile R, Mauri M, Cazzullo C L.
Le valpromide (Depamide) dans le traitement d'etats psychotiques aigus.
Acta Psychiat Belg.
1986;
86
297-304
-
5
Amen D G, Stubblefield M, Carmicheal B, Thisted R.
Brain SPECT findings and aggressiveness.
Ann Clin Psychiatry.
1996;
8
129-137
-
6 Andreasen N C, Flaum M, Arndt S, Alliger R, Swayze V W. Positive and negative symptoms: assessment and validity. In: Morneros A, Andreasen NC, Tsuang M (eds) Negative versus positive schizophrenia. Berlin; Springer 1991: 28-51
-
7
Asghari V, Wang J F, Reiach J S, Young L T.
Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells.
Brain Res Mol Brain Res.
1998;
58
95-102
-
8
Baetz M, Bowen R C.
Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy.
Can J Psychiat.
1998;
43
73-77
-
9
Benes F M.
Evidence for altered trisynaptic circuitry in schizophrenic hippocampus.
Biol Psychiatry.
1999;
46
589-599
-
10
Bertolino A, Callicott J H, Elman I, Mattay V S, Tedeschi G, Frank A J, Breier A, Weinberger D R.
Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study.
Biol Psychiat.
1998;
43
641-648
-
11
Biggs C S, Pearce B R, Fowler L J, Whitton P S.
The effect of sodium valproate on extracellular GABA and other aminoacids in the rat ventral hippocampus: an in vivo microdialysis study.
Brain Res.
1992;
594
138-142
-
12
Bolanos J P, Medina J M.
Effect of valproate on the metabolism of the central nervous system.
Life Sciences.
1997;
60
1933-1942
-
13
Brockington I F, Perris C, Kendell R E, Hillier V E, Wainwright S.
The course and outcome of cycloid psychosis.
Psychol Medicine.
1982;
12
97-105
-
14
Buchhalter J R, Dichter M A.
Effects of valproic acid in cultured mammalian neurons.
Neurology.
1986;
36
259-262
-
15
Buda M, Tsuang M T, Fleming J A.
Causes of death in DSM-III schizophrenics and other psychotics (atypical group): a comparison with the general population.
Arch Gen Psychiatry.
1998;
45
283-285
-
16
Burns A, Jacoby R, Levy R.
Psychiatric phenomenon in Alzheimer's disease. IV: Disorders of behaviour.
Br J Psychiat.
1990;
157
86-94
-
17
Callicott J H, Egan M F, Bertolino A, Mattay V S, Langheim F JP, Duyn J H, Frank J A, Weinberger D R.
Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype.
Biol Psychiatry.
1988;
44
941-950
-
18
Chong S A, Tan C H, Lee E L, Liow P H.
Augmentation of resperidone with valproic acid.
J Clin Psychiat.
1998;
59
430
-
19
Citrome L, Levine J, Allingham B.
Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health.
Psychiatry Quarterly.
1998;
69
283-300
-
20
Clemente C D, Chase M H.
Neurological substrates of aggressive behavior.
Ann Rev Physiol.
1973;
35
329-356
-
21
Cutting J C, Clarke A W, Mann A H.
Cycloid psychosis: an investigation of the diagnostic concept.
Psychol Medicine.
1978;
8
637-648
-
22
Davis R, Peters D H, McTavish D.
Valproic acid - a reappraisal of its pharmacological properties and clinical efficacy in epilepsy.
Drugs.
1994;
47
332-372
-
23
Dailey J W, Reith M E, Yan Q S, Li M Y, Jobe P C.
Carbamazepine increases extracellular serotonin concentration: lack of antagonism by terodotoxin or zero Ca2+.
Eur J Pharmacol.
1997;
328
153-162
-
24
Dailey J W, Reith M E, Steidley K R, Milbrandt J C, Jobe P C.
Carbamazepine-induced release of serotonin from rat hippocampus in vitro.
Epilepsia.
1998;
39
1054-1063
-
25 Delgado J M. Aggression and defense under cerebral ratio control. In: Clemente CD, Lindsley DB (eds) Aggression and defense. . Los Angeles; Univ of California Press 1967
-
26
Deltito J A, Levitan J, Damore J, Hajal F, Zambenedetti M.
Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescence psychiatric patients.
Acta Psychiat Scand.
1998;
97
236-240
-
27
Diener H C, Kaube H, Limmroth V.
A practical guide to the management and prevention of migraine.
Drugs.
1998;
56
811-824
-
28
Dixon J F, Hokin L E.
The antibipolar drug valporate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates.
Proc Natl Acad Sci USA.
1997;
94
4757-4760
-
29
Donovan S J, Susser E S, Nunes E V, Stewart J W, Quitkin F M, Klein D F.
Divalproex treatment of disrupture adolescents: a report of 10 cases.
J Clin Psychiatry.
1997;
56
12-15
-
30
Dose M, Hellweg R, Yassouridis A, Theison M, Emrich H M.
Combined treatment of schizophrenic psychoses with haloperidol and valproate.
Pharmacopsychiatry.
1998;
31
122-125
-
31
Emrich H M, Dose M, Von Zerssen D.
The use of sodium valproate, carabamazepine, and oxcarbazepine in patients with affective disorders.
J Affect Disord.
1985;
8
243-250
-
32
Finley P, Warner D.
Potential impact of valproic acid therapy on clozapine disposition.
Biol Psychiat.
1994;
36
487-488
-
33
Fisk G G, York S M.
The effect of sodium valproate on tardive dyskinesia - revisited.
Br J Psychiatry.
1987;
150
542-546
-
34 Ganong W F. Nervous system. Los Altos; Lange 1977
-
35
Gastaut H.
Les troubles du comportement chez les epileptiques psychomoteurs.
Rev Neurol.
1955;
92
55-62
-
36
Gean P-W, Huang C-C, Hung C-R, Tsai J-J.
Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices.
Brain Res Bull.
1994;
33
333-336
-
37
Godin Y, Heiner L, Mark J, Mandel P.
Effects of DI-n-proylacetate, and anticonvulsive compound, on GABA metabolism.
N Neurochem.
1969;
16
869-873
-
38
Grossmann F.
A review of anticonvulsants in treating agitated demented elderly patients.
Pharmacotherapy.
1998;
18
600-606
-
39
Haas S, Vincent K, Holy J, Lippmann S.
Divalproex: a possible treatment alternative for demented, elderly aggressive patients.
Annals Clin Psychiatry.
1997;
9
145-147
-
40 Hardman J G, Limbird L E, Molinoff P B, Ruddon R W, Goodman L S, Gilman A. The pharmacological basis of therapeutics. New York; McGraw-Hill 1996
-
41
Herrmann N.
Valproic acid treatment of agitation in dementia.
Can J Psychiatry.
1998;
43
69-72
-
42
Hill D, Mitchell W.
Epileptic anamnesis.
Fol Psychiat Neerl.
1952;
56
718-725
-
43
Hilty D M, Rodriguez G D, Hales R E.
Intravenous valproate for rapid stabilization of agitationin neuropsychiatric disorders.
J Neuropsychiat Clin Neurosci.
1998;
10
356-366
-
44 Hitzemann R J, Harris R A, Loh H H. Pharmacological, developmental, and physiological regulation of synaptic membrane phospholipids.Phospholipids and cellular regulation, vol. I. In: Shinitzky M (ed) Phospholipids and cellular regulation, vol. I. Boca Raton, FL 1985: 97-130
-
45
Hyde T, Casanova M, Kleinman J E, Weinberger D R.
Neuroanatomical and neurochemical pathology in schizophrenia.
Am Psychiat Press Rev Psychiatry.
1991;
10
7-23
-
46
Hyman S E, Nestler E J.
Initiation and adaptation: a paradigm for understanding psychotropic drug action.
Am J Psychiat.
1996;
153
151-162
-
47
Kahn D, Stevenson E, Douglas C J.
Effect of sodium valproate in three patients with organic brain syndrome.
Am J Psychiat.
1988;
145
1010-1011
-
48
Kastner T, Finesmith R, Walsh K.
Long-term administration of valproic acid in the treatment of affective symptoms in mental retardation.
J Clin Psychopharmacol.
1993;
13
448-451
-
49
Kausen J, Zimmermann P, Funfgeld E W, Klenke D, Henkel H.
Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.
Neuropsychobiology.
1984;
11
59-64
-
50 Kavoussi R, Armstead P, Coccaro E. The neurobiology of impulse aggression. In: Fava M (ed) Anger, Aggresion, and Violence. The Psychiatric Clinics of North America 1997 20: 395-403
-
51
Kavoussi R J, Coccaro E F.
Divalproex sodium for impulse aggressive behavior in patients with personality disorder.
J Clin Psychiat.
1998;
59
676-680
-
52
Keck P E, McElroy S L, Friedman L M.
Valproate and carbamazepine in the treatment of panic and post-traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes.
J Clin Psychopharmacology.
1992;
12
36S-41S
-
53
Keck P E, McElroy S L, Strakowski S M.
New developments in the pharmacologic treatment of schizoaffective disorder.
J Clin Psychiat.
1996;
57
41-48
-
54
Kennedy D, Koren G.
Valproic acid use in psychiatry: issues in treating women of reproductive age.
J Psychiatry Neurosci.
1998;
23
223-228
-
55 Keshavan M S, Pettegrew J W. Magnetic resonance spectroscopy in schizophrenia and psychotic disorders. In: Krishnan KRR (ed) Brain Imaging Psychiatry. New York; Marcell-Dekker Inc 1997: 381-400
-
56
Ko G N, Korpi E R, Freed W J, Zalcman S J, Bigelow L B.
Effects of valporic acid on behavior and plasma amino acid concentration in chronic schizophrenic patients.
Biol Psychiatry.
1985;
20
209-215
-
57 Leonhard K. Aufteilung der endogenen Psychosen. Berlin; Akademie-Verlag 1957
-
58
Lewin J, Sumners D.
Successful treatment of episodic dyscontrol with carbamazepine.
Br J Psychiat.
1992;
161
261-262
-
59 Lewis S W. The secondary schizophrenias. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 324-340
-
60
Licht R W.
Drug treatment of mania: a critical review.
Acta Psychiat Scand.
1998;
97
387-397
-
61
Linnoila M, Viukari M, Hietala O.
Effect of sodium valproate on tardive dyskinesia.
Br J Psychiatry.
1976;
129
140-119
-
62
Lipska B K, Jaskiw G E, Weinberger D R.
Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia.
Neuropsychopharmacol.
1993;
9
67-75
-
63
Löscher W.
Effect of inhibitors of GABA aminotransferase on the metabolism of gGABA in brain tissue and synaptosomal fractions.
J Neurochem Res.
1981;
36
1521-1527
-
64
Löscher W.
In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats.
Neurosci Lett.
1993;
160
177-180
-
65
Löscher W.
Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain.
Neurochem Res.
1993;
18
485-202
-
66
Longo L P, Salzman C.
Valproic acid effects on serum concentration of clozapine and norclozapine.
Am J Psychiatry.
1995;
152
650
-
67
Lott A D, McElroy S L, Keys M A.
Valproate in the treatment of behavioral agitation in elderly patients with dementia.
J Neuropsychiatry.
1995;
7
314-319
-
68
Luder A S, Parks J K, Frerman F, Parker W D.
Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions.
J Clin Invest.
1990;
86
1574-1581
-
69
Meyer M C, Baldessarini R J, Goff D C, Centorrino F.
Clinically significant interactions of psychotropic agents with antipsychotic drugs.
Drug Safety.
1996;
15
333-346
-
70
McElroy S L, Keck P E, Pope H G.
Sodium valproate: its use in primary psychiatric disorders.
J Clin Psychopharmacology.
1987;
7
16-24
-
71 McElroy S L, Keck P E, Pope H G, Hudson J I. Valproate in primary psychiatric disorders: Literature review and clinical experience in a private psychiatric hospital. In: McElroy SL, Pope HG (eds) Use of anticonvulsants in psychiatry: recent advances. Oxford; Healt Care Inc, Clifton 1988: 25-42
-
72
McElroy S L, Keck P E, Pope H G, Hudson J I.
Valproate in psychiatric disorders: literature review and clinical guidelines.
J Clin Psychiatry.
1989;
50
((Suppl. 3))
23-29
-
73
Meltzer H Y.
Treatment of the neuroleptic-nonreponsive schizophrenic patient.
Schiz Bull.
1992;
18
515-542
-
74
Morinigo A, Martin J, Gonzalez S, Mateo I.
Treatment of resistant schizophrenia with valporate and neuroleptic drugs.
Hillside J Clin Psychiat.
1989;
11
199-207
-
75
Olney J W, Farber N B.
Glutamate receptor dysfunction and schizophrenia.
Arch Gen Psychiat.
1995;
52
998-1007
-
76
Paredes R G, Karam P, Highland L, Agmo A.
GABAergic drugs and socio-sexual behavior.
Pharmacol Biochem Behavior.
1997;
58
291-298
-
77
Perreault P, Tancredi V, Avoli M.
Failure of the antiepileptic drug valproic acid to modify synaptic and non-synaptic responses of CA1 hippocampal pyramidal cells maintained “in vitro”.
Epilepsy Res.
1989;
3
227-231
-
78
Phillips I, Martin K F, Thompson K S, Heal D J.
Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine.
Eur J Pharmacol.
1997;
337
189-195
-
79
Preisendörfer U, Zeise M L, Klee M R.
Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons in vitro.
Brain Res.
1987;
435
213-219
-
80
Prevey M L, Delaney R C, Cramer J A, Cattanach L, Collins J F, Mattson R H.
Effect of valproate on cognitive functioning.
Arch Neurology.
1996;
53
1008-1016
-
81
Rauch S L, Hitzemann R J.
Developmental changes in synaptic membrane order: A comparison of regions in the rat brain.
Dev Brain Res.
1986;
26
221-227
-
82
Reuttens S, Castle D.
Valproate and neuroleptic medication.
Br J Psychiatry.
1997;
170
484-485
-
83
Roy-Byrne P P, Ward N G, Donnelly P J.
Valproate in anxiety and withdrawal syndromes.
J Clin Psychiat.
1989;
50
((Suppl. 3))
44-48
-
84
Sachdev P, Smith J S, Matheson J, Last P, Blumbergs P.
Amygdalo-hippocamectomy for pathological aggression.
Aust. N Z J Psychiatry.
1992;
26
671-676
-
85
Sawaya M CB, Horton R W, Meldrun B S.
Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA.
Epilepsia.
1975;
16
649-655
-
86 Seger D L. Antiepileptic drug actions. In: Haddad LM, Shannon MW (eds) Clinical management of poisoning and drug overdose. Winchester; Saunders 1998
-
87 Shinitsky M. Phospholipids and cellular regulation. Boca Raton; Fl: CRC 1985
-
88
Silverman R B, Andruszkiezwicz R, Nanavati S M, Taylor C P, Vartanian M G.
3-alkyl-4-aminobutyric acids; the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase.
J Med Chem.
1991;
34
2295-2298
-
89
Stein D J, Simeon D, Frenkel M, Islam M N, Hollander E.
An open trial of valproate in borderline personality disorder.
J Clin Psychiatry.
1995;
56
506-510
-
90 Taylor P J. Schizophrenia and the risk of violence. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 163-183
-
91 Tsuang M T, Levitt J J, Simpson J C. Schizoaffective disorder. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford; Blackwell Science 1995: 46-57
-
92
Tulloch I F, Walter D S, Howe G M, Howe S J.
The relationship between plasma concentration of valproic acid and its anticonvulsant and behavioral effects in rat.
Neuropharmacology.
1982;
21
555-562
-
93
Van Blitterswijk W J, Van Hoeven R P, Van der Meer B W.
Lipid structural order parameter (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements.
Biochem Biophys Acta.
1981;
644
323-332
-
94
Van der Laan J W, De Boer T H, Bruinvels J.
Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase.
J Neurochem.
1979;
32
1769-1780
-
95
Volkow N D, Tancredi L R, Grant C, Gillespie H.
Brain glucose metabolism in violent psychiatric patients: a preliminary study.
Psychiat Res.
1995;
61
243-253
-
96
Vorhees C V, Rauch S, Hitzemann R J.
Effects of short-term prenatal alcohol exposure on neuronal membrane order in rats.
Dev Brain Res.
1988;
38
161-166
-
97
Vorhees C V, Rauch S L, Hitzemann R J.
Prenatal phenytoin exposure decreases neuronal membrane order in rat offspring hippocampus.
Int J Dev Neuroscience.
1990;
8
283-288
-
98
Vorhees C V.
Fetal anticonvulsant syndrome in rats: Dose- and period-response relationships of prenatal diphenylhydantoin, trimehadione, and phenobarbital exposure on the structural and functional development of the offspring.
J Pharmacol Exp Ther.
1983;
227
274-287
-
99
Vorhees C V.
Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content.
Neurobehav Toxicol Teratol.
1985;
227
274-287
-
100
Vorhees C V.
Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats.
Psychopharmacol.
1987;
92
173-179
-
101
Vorhees C V, Rauch S L, Hitzemann R J.
Prenatal valproic acid exposure decreases neuronal membrane order in rat offspring hippocampus and cortex.
Neurotox Teratology.
1991;
13
471-474
-
102
Vriend J P, Alexiuk N AM.
Effects of valproate on amino acid and monoamine concentrations in triatum of audiogenic seizure-prone Balb/c mice.
Mol Chem Neuropatol.
1996;
27
307-324
-
103
Wang J-F, Brown C, Young L T.
Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78.
Mol Pharmacol.
1999;
55
521-527
-
104
Weinberger D R.
Implications of normal brain development for the pathogenesis of schizophrenia.
Arch Gen Psychiatry.
1987;
44
660-669
-
105
Weinberger D R.
Cell Biology of the hippocampal formation in schizophrenia.
Biol Psychiatry.
1999;
45
395-402
-
106
Whitton P S, Oreskovic D, Jernej B, Bulat M.
Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain.
J Pharm Pharmacol.
1985;
37
199-200
-
107
Wilcox J A.
Divalproex sodium as a treatment for borderline personality disorder.
Ann Clin Psych.
1995;
7
33-37
-
108
Winterer G, Ziller M, Dorn H, Frick K, Mulert C, Wuebben Y, Herrmann W M, Coppola R.
Schizophrenia: Reduced Signal-to-Noise Ratio and Impaired Phase-Locking during Information Processing.
Clin Neurophysiol.
2000a;
3
837-849
-
109 Winterer G, Egan M F, Rädler T, Coppola C, Weinberger D R. An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia. Schizophr Res (in press)
-
110
Wolkowitz O M.
Rational polypharmacy in schizophrenia.
Ann Clin Psychiatry.
1993;
5
79-90
-
111
Wong M T, Lumsden J, Fenton G W.
Electroencephalography, computed tomography and violence ratings of male patients in a maximum security mental hospital.
Acty Psychiat Scand.
1994;
90
97-101
-
112
Wroblewski B A, Joseph A B, Kupfer J, Kalliel K.
Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired brain injury.
Brain Injury.
1997;
11
37-47
-
113
Yudofsky S, Silver J, Schneider S.
Pharmacologic traetment of aggression.
Psychiatr Ann.
1987;
2
397-407
-
114
Zeise M L, Kasparow S, Zieglgänsberger W.
Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro.
Brain Res.
1991;
544
345-348
G. Winterer
National Institutes of Health
National Institute of Mental Health
Clinical Brain Disorder Branch
10 Center Drive, Room 4s235 MSC 1379
Bethesda, MD, 20892-1379
USA
Phone: 001-301-594-0874
Email: wintereg@intra.nimh.nih.gov
